Novo Nordisk's Wegovy Shows Significant Improvement in MASH Trial for Liver Disease

Nov 1, 2024, 01:22 PM

Novo Nordisk's semaglutide 2.4 mg, marketed as Wegovy, has demonstrated significant improvements in liver fibrosis and MASH (metabolic-associated steatohepatitis) resolution in the ESSENCE trial. The trial, which involved 1,200 adults, showed that after 72 weeks, 37% of patients treated with semaglutide experienced improvement in liver fibrosis compared to 22.5% on placebo. Additionally, 62.9% of treated patients achieved MASH resolution versus 34.1% on placebo. Wegovy, primarily a weight-loss drug, also showed potential in treating obesity-associated liver disease. The company plans to file for regulatory approvals in the US and EU in the first half of 2025. Detailed results from the ESSENCE trial will be presented at an upcoming scientific conference.